Mark Hyman Rapaport
Overview
Explore the profile of Mark Hyman Rapaport including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
1218
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Giollabhui N, Mischoulon D, Dunlop B, Kinkead B, Schettler P, Liu R, et al.
Brain Behav Immun Health
. 2023 Jul;
32:100666.
PMID: 37503359
Cognitive impairment related to major depressive disorder (MDD) is highly prevalent, debilitating and is lacking in effective treatments; dysregulated inflammatory physiology is a putative mechanism and may represent a therapeutic...
2.
Rapaport M, Schettler P, Larson E, Edwards S, Dunlop B, Rakofsky J, et al.
J Bodyw Mov Ther
. 2023 Feb;
33:176-181.
PMID: 36775516
Objective: Generalized Anxiety Disorder (GAD) is a prevalent and costly disorder, and many patients may prefer non-traditional treatment. A proof-of-concept study demonstrated the efficacy of Swedish Massage Therapy (SMT) as...
3.
Lamon-Fava S, Liu M, Dunlop B, Kinkead B, Schettler P, Felger J, et al.
Neuropsychopharmacology
. 2023 Jan;
48(6):929-935.
PMID: 36635595
Chronic inflammation has been implicated in the pathophysiology of major depressive disorder (MDD). Activating the resolution of inflammation through ω-3 fatty acid supplementation may prove to be a successful therapeutic...
4.
5.
Mischoulon D, Dunlop B, Kinkead B, Schettler P, Lamon-Fava S, Rakofsky J, et al.
J Clin Psychiatry
. 2022 Aug;
83(5).
PMID: 36005883
This study compared the impact of 3 eicosapentaenoic acid (EPA) doses versus placebo on inflammatory biomarkers and depressive symptoms. Sixty-one unmedicated adults (75% female; 45.5 ± 13.8 years) with major...
6.
Lamon-Fava S, So J, Mischoulon D, Ziegler T, Dunlop B, Kinkead B, et al.
Prostaglandins Leukot Essent Fatty Acids
. 2020 Dec;
164:102219.
PMID: 33316626
Background: Eicosapentaenoic acid (EPA) supplementation is an effective treatment option in major depressive disorder (MDD) associated with chronic low-grade inflammation. EPA is the precursor of specialized pro-resolving lipid mediators (SPMs)...
7.
Rapaport M, Schettler P, Larson E, Dunlop B, Rakofsky J, Kinkead B
Complement Ther Med
. 2020 Nov;
56:102593.
PMID: 33197668
Acute treatment of Generalized Anxiety Disorder often requires 3 months or more of care in order to optimize response. As part of an exploratory grant we have previously demonstrated that...
8.
9.
Goldsmith D, Rapaport M
Front Psychiatry
. 2020 Mar;
11:46.
PMID: 32153436
Negative symptoms of schizophrenia are debilitating and chronic in nature, are difficult to treat, and contribute to poor functional outcomes. Motivational deficits are a core negative symptom and may involve...
10.
Rapaport M, Schettler P, Larson E, Carroll D, Sharenko M, Nettles J, et al.
Focus (Am Psychiatr Publ)
. 2020 Jan;
16(1):24-31.
PMID: 31975897
This article reviews the current state of knowledge of the role of massage therapy in the treatment of common psychiatric disorders and symptoms. It briefly discusses the prevalence of psychiatric...